Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI) : a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study

Hernström, Veronica LU orcid ; Josefsson, Viktoria LU ; Sartor, Hanna LU ; Schmidt, David LU ; Larsson, Anna Maria LU ; Hofvind, Solveig ; Andersson, Ingvar LU ; Rosso, Aldana LU orcid ; Hagberg, Oskar LU and Lång, Kristina LU (2025) In The Lancet Digital Health 7(3). p.175-183
Abstract

Background: Emerging evidence suggests that artificial intelligence (AI) can increase cancer detection in mammography screening while reducing screen-reading workload, but further understanding of the clinical impact is needed. Methods: In this randomised, controlled, parallel-group, non-inferiority, single-blinded, screening-accuracy study, done within the Swedish national screening programme, women recruited at four screening sites in southwest Sweden (Malmö, Lund, Landskrona, and Trelleborg) who were eligible for mammography screening were randomly allocated (1:1) to AI-supported screening or standard double reading. The AI system (Transpara version 1.7.0 ScreenPoint Medical, Nijmegen, Netherlands) was used to triage screening... (More)

Background: Emerging evidence suggests that artificial intelligence (AI) can increase cancer detection in mammography screening while reducing screen-reading workload, but further understanding of the clinical impact is needed. Methods: In this randomised, controlled, parallel-group, non-inferiority, single-blinded, screening-accuracy study, done within the Swedish national screening programme, women recruited at four screening sites in southwest Sweden (Malmö, Lund, Landskrona, and Trelleborg) who were eligible for mammography screening were randomly allocated (1:1) to AI-supported screening or standard double reading. The AI system (Transpara version 1.7.0 ScreenPoint Medical, Nijmegen, Netherlands) was used to triage screening examinations to single or double reading and as detection support highlighting suspicious findings. This is a protocol-defined analysis of the secondary outcome measures of recall, cancer detection, false-positive rates, positive predictive value of recall, type and stage of cancer detected, and screen-reading workload. This trial is registered at ClinicalTrials.gov, NCT04838756 and is closed to accrual. Findings: Between April 12, 2021, and Dec 7, 2022, 105 934 women were randomly assigned to the intervention or control group. 19 women were excluded from the analysis. The median age was 53·7 years (IQR 46·5–63·2). AI-supported screening among 53 043 participants resulted in 338 detected cancers and 1110 recalls. Standard screening among 52 872 participants resulted in 262 detected cancers and 1027 recalls. Cancer-detection rates were 6·4 per 1000 (95% CI 5·7–7·1) screened participants in the intervention group and 5·0 per 1000 (4·4–5·6) in the control group, a ratio of 1·29 (95% CI 1·09–1·51; p=0·0021). AI-supported screening resulted in an increased detection of invasive cancers (270 vs 217, a proportion ratio of 1·24 [95% CI 1·04–1·48]), wich were mainly small lymph-node negative cancers (58 more T1, 46 more lymph-node negative, and 21 more non-luminal A). AI-supported screening also resulted in an increased detection of in situ cancers (68 vs 45, a proportion ratio of 1·51 [1·03–2·19]), with about half of the increased detection being high-grade in situ cancer (12 more nuclear grade III, and no increase in nuclear grade I). The recall and false-positive rate were not significantly higher in the intervention group (a ratio of 1·08 [95% CI 0·99–1·17; p=0·084] and 1·01 [0·91–1·11; p=0·92], respectively). The positive predictive value of recall was significantly higher in the intervention group compared with the control group, with a ratio of 1·19 (95% CI 1·04–1·37; p=0·012). There were 61 248 screen readings in the intervention group and 109 692 in the control group, resulting in a 44·2% reduction in the screen-reading workload. Interpretation: The findings suggest that AI contributes to the early detection of clinically relevant breast cancer and reduces screen-reading workload without increasing false positives. Funding: Swedish Cancer Society, Confederation of Regional Cancer Centres, and Swedish governmental funding for clinical research.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Digital Health
volume
7
issue
3
pages
175 - 183
publisher
Elsevier
external identifiers
  • scopus:85218464312
  • pmid:39904652
ISSN
2589-7500
DOI
10.1016/S2589-7500(24)00267-X
project
Mammography Screening with Artificial Intelligence
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
id
b86e819c-27f5-4865-a125-5d6fa8214156
date added to LUP
2025-03-08 10:28:22
date last changed
2025-06-29 03:46:09
@article{b86e819c-27f5-4865-a125-5d6fa8214156,
  abstract     = {{<p>Background: Emerging evidence suggests that artificial intelligence (AI) can increase cancer detection in mammography screening while reducing screen-reading workload, but further understanding of the clinical impact is needed. Methods: In this randomised, controlled, parallel-group, non-inferiority, single-blinded, screening-accuracy study, done within the Swedish national screening programme, women recruited at four screening sites in southwest Sweden (Malmö, Lund, Landskrona, and Trelleborg) who were eligible for mammography screening were randomly allocated (1:1) to AI-supported screening or standard double reading. The AI system (Transpara version 1.7.0 ScreenPoint Medical, Nijmegen, Netherlands) was used to triage screening examinations to single or double reading and as detection support highlighting suspicious findings. This is a protocol-defined analysis of the secondary outcome measures of recall, cancer detection, false-positive rates, positive predictive value of recall, type and stage of cancer detected, and screen-reading workload. This trial is registered at ClinicalTrials.gov, NCT04838756 and is closed to accrual. Findings: Between April 12, 2021, and Dec 7, 2022, 105 934 women were randomly assigned to the intervention or control group. 19 women were excluded from the analysis. The median age was 53·7 years (IQR 46·5–63·2). AI-supported screening among 53 043 participants resulted in 338 detected cancers and 1110 recalls. Standard screening among 52 872 participants resulted in 262 detected cancers and 1027 recalls. Cancer-detection rates were 6·4 per 1000 (95% CI 5·7–7·1) screened participants in the intervention group and 5·0 per 1000 (4·4–5·6) in the control group, a ratio of 1·29 (95% CI 1·09–1·51; p=0·0021). AI-supported screening resulted in an increased detection of invasive cancers (270 vs 217, a proportion ratio of 1·24 [95% CI 1·04–1·48]), wich were mainly small lymph-node negative cancers (58 more T1, 46 more lymph-node negative, and 21 more non-luminal A). AI-supported screening also resulted in an increased detection of in situ cancers (68 vs 45, a proportion ratio of 1·51 [1·03–2·19]), with about half of the increased detection being high-grade in situ cancer (12 more nuclear grade III, and no increase in nuclear grade I). The recall and false-positive rate were not significantly higher in the intervention group (a ratio of 1·08 [95% CI 0·99–1·17; p=0·084] and 1·01 [0·91–1·11; p=0·92], respectively). The positive predictive value of recall was significantly higher in the intervention group compared with the control group, with a ratio of 1·19 (95% CI 1·04–1·37; p=0·012). There were 61 248 screen readings in the intervention group and 109 692 in the control group, resulting in a 44·2% reduction in the screen-reading workload. Interpretation: The findings suggest that AI contributes to the early detection of clinically relevant breast cancer and reduces screen-reading workload without increasing false positives. Funding: Swedish Cancer Society, Confederation of Regional Cancer Centres, and Swedish governmental funding for clinical research.</p>}},
  author       = {{Hernström, Veronica and Josefsson, Viktoria and Sartor, Hanna and Schmidt, David and Larsson, Anna Maria and Hofvind, Solveig and Andersson, Ingvar and Rosso, Aldana and Hagberg, Oskar and Lång, Kristina}},
  issn         = {{2589-7500}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{175--183}},
  publisher    = {{Elsevier}},
  series       = {{The Lancet Digital Health}},
  title        = {{Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI) : a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study}},
  url          = {{http://dx.doi.org/10.1016/S2589-7500(24)00267-X}},
  doi          = {{10.1016/S2589-7500(24)00267-X}},
  volume       = {{7}},
  year         = {{2025}},
}